GF9-LPC loaded TREM-1 receptor inhibitor (SignaBlok)

N/A

Report date: 2025/03/20 16:06:26

Base Information

Drug NameGF9-LPC loaded TREM-1 receptor inhibitor (SignaBlok)
Drug Alias NameGF9-lipopeptide complex (SignaBlok)
ClassificationBiologics > Protein drugs > Recombinant polypeptideDiagnostic agent (In vivo)
Mechanisms of ActionTriggering receptor expressed on myeloid cells 1 inhibitors
TargetsTriggering receptor expressed on myeloid cells 1
Therapy Area/IndicationsInflammationRetinopathy of PrematurityArthritis, Rheumatoid +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSignaBlok Inc
China Registration ClassN/A

Develop Information

Active CompaniesSignaBlok Inc
Inactive CompaniesN/A
Active IndicationsInflammationRetinopathy of PrematurityArthritis, Rheumatoid +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A